Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AIM ImmunoTech Inc. (AIM : AMEX)

• Company Description    AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is based in Ocala, Florida. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $0.25 Daily Weekly Monthly 20 Day Moving Average: 748,170 shares Shares Outstanding: 14.56 (millions) Market Capitalization: $3.63 (millions) Beta: 1.20 52 Week High: $8.39 52 Week Low: $0.21 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -29.94% -30.45% 12 Week -51.99% -53.30% Year To Date -77.96% -79.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2117 SW HIGHWAY 484 - OCALA,FL 34473 USA ph: 352-448-7797 fax: 215-988-1739 aim@jtcir.com http://www.aimimmuno.com

• General Corporate Information    Officers Thomas K. Equels - Chief Executive Officer & President William Mitchell - Chairman of the Board Robert Dickey IV - Chief Financial Officer Nancy Bryan - Director David Chemerow - Director Peer Information AIM ImmunoTech Inc. (GSAC) AIM ImmunoTech Inc. (CASIF) AIM ImmunoTech Inc. (ALCD.) AIM ImmunoTech Inc. (OMNN) AIM ImmunoTech Inc. (CGPI.) AIM ImmunoTech Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 00901B303 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 14.56 Most Recent Split Date: 6.00 (0.01:1) Beta: 1.20 Market Capitalization: $3.63 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.12 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.63 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.96 Price/Cash Flow: - Price / Sales: 38.58 EPS Growth vs. Year Ago Period: 86.20% vs. Previous Quarter: -56.82% Sales Growth vs. Year Ago Period: 37.50% vs. Previous Quarter: 4.76% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - -177.72 12/31/25 - -209.50 Current Ratio 06/30/26 - - 03/31/26 - 1.01 12/31/25 - 0.53 Quick Ratio 06/30/26 - - 03/31/26 - 1.01 12/31/25 - 0.53 Operating Margin 06/30/26 - - 03/31/26 - -11,339.36 12/31/25 - -12,887.50 Net Margin 06/30/26 - - 03/31/26 - -14,123.40 12/31/25 - -15,861.36 Pre-Tax Margin 06/30/26 - - 03/31/26 - -14,123.40 12/31/25 - -15,861.36 Book Value 06/30/26 - - 03/31/26 - 0.26 12/31/25 - -2.99 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.10 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - 8.99 12/31/25 - -

Powered by Zacks Investment Research ©